Stock Analysis on Net
Stock Analysis on Net

Abiomed Inc. (NASDAQ:ABMD)

This company has been moved to the archive! The financial data has not been updated since November 3, 2022.

Adjustments to Financial Statements

Microsoft Excel

Adjustments to Current Assets

Abiomed Inc., adjusted current assets

US$ in thousands

Microsoft Excel
Mar 31, 2022 Mar 31, 2021 Mar 31, 2020 Mar 31, 2019 Mar 31, 2018 Mar 31, 2017
As Reported
Current assets 976,473 787,965 635,863 677,197 494,271 326,958
Adjustments
Add: Allowance for credit losses 624 774 1,202 1,040 320 282
After Adjustment
Adjusted current assets 977,097 788,739 637,065 678,237 494,591 327,240

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).


The current asset position demonstrates significant growth from March 31, 2017, through March 31, 2022. Total current assets rose from 326,958 thousand US dollars to 976,473 thousand US dollars, representing a substantial increase in short-term resources over the observed period. A temporary contraction is noted in March 2020, where current assets decreased to 635,863 thousand US dollars from the previous year's 677,197 thousand US dollars, before resuming a strong upward trajectory in the subsequent two years.

Asset Growth Trajectory
A consistent upward trend is observed, with the total value of current assets nearly tripling over the six-year span. This indicates a significant expansion of the organization's liquidity base.
Analysis of Asset Adjustments
Adjusted current assets are consistently higher than the reported current assets across all periods. However, the variance remains marginal, ranging from a minimum of 282 thousand US dollars in 2017 to a maximum of 1,202 thousand US dollars in 2020.
Materiality of Adjustments
The difference between reported and adjusted current assets is negligible relative to the total asset base. Consequently, these adjustments do not materially alter the interpretation of the company's financial health or liquidity trends.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Adjustments to Total Assets

Abiomed Inc., adjusted total assets

US$ in thousands

Microsoft Excel
Mar 31, 2022 Mar 31, 2021 Mar 31, 2020 Mar 31, 2019 Mar 31, 2018 Mar 31, 2017
As Reported
Total assets 1,673,393 1,494,359 1,216,462 1,054,346 786,375 550,414
Adjustments
Add: Operating lease right-of-use asset (before adoption of FASB Topic 842)1 — — — 14,274 10,089 7,462
Add: Allowance for credit losses 624 774 1,202 1,040 320 282
Less: Deferred tax assets2 10,552 11,380 43,336 77,502 70,746 34,723
After Adjustment
Adjusted total assets 1,663,465 1,483,753 1,174,328 992,158 726,038 523,435

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).

1 Operating lease right-of-use asset (before adoption of FASB Topic 842). See details »

2 Deferred tax assets. See details »


A consistent and significant upward trajectory in both total assets and adjusted total assets is observed from March 31, 2017, through March 31, 2022. Total assets grew from 550,414 thousand US$ to 1,673,393 thousand US$, representing a substantial expansion of the company's asset base over the six-year period.

Asset Growth Velocity
The most rapid expansion occurred between 2017 and 2019, with total assets increasing by approximately 91.5% during this timeframe. While growth continued through 2022, the rate of increase moderated in the final year, rising by 12% between March 31, 2021, and March 31, 2022.
Adjustment Variance Analysis
A positive variance exists between total assets and adjusted total assets throughout the entire period. The absolute difference peaked in 2019 at 62,188 thousand US$. This indicates that specific asset components were systematically excluded or modified to arrive at the adjusted figure for analytical purposes.
Convergence Trend
A notable trend of convergence is observed between the reported total assets and the adjusted total assets. In 2017, the adjustment represented approximately 4.9% of total assets; by 2018, this increased to 7.7%. However, from 2020 onward, the gap narrowed sharply. By March 31, 2022, the difference was reduced to 9,928 thousand US$, representing only 0.6% of total assets, suggesting that the factors necessitating the adjustment became less material relative to the overall size of the balance sheet.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Adjustments to Current Liabilities

Abiomed Inc., adjusted current liabilities

US$ in thousands

Microsoft Excel
Mar 31, 2022 Mar 31, 2021 Mar 31, 2020 Mar 31, 2019 Mar 31, 2018 Mar 31, 2017
As Reported
Current liabilities 138,457 128,969 131,885 105,998 84,682 69,617
Adjustments
Less: Current deferred revenue 26,362 24,322 19,147 16,393 14,970 10,495
Less: Current product warranty 1,935 2,053 1,818 1,272 1,081 717
After Adjustment
Adjusted current liabilities 110,160 102,594 110,920 88,333 68,631 58,405

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).


An analysis of the financial obligations from 2017 to 2022 reveals a consistent upward trajectory in both reported and adjusted current liabilities. Total current liabilities increased from 69,617 thousand US dollars in 2017 to 138,457 thousand US dollars by 2022, representing an overall growth of approximately 98.9%. Adjusted current liabilities followed a similar pattern, rising from 58,405 thousand US dollars to 110,160 thousand US dollars over the same period.

Growth Trends and Volatility
A period of sustained growth is observed between 2017 and 2020, with current liabilities increasing annually. A slight contraction occurred in 2021, where current liabilities decreased by 2.2% and adjusted current liabilities decreased by 7.5%. This trend reversed in 2022, with both metrics returning to growth, increasing by approximately 7.4%.
Adjustment Variance Analysis
The discrepancy between reported current liabilities and adjusted current liabilities has expanded in absolute terms over the six-year period. In 2017, the adjustment amount was 11,212 thousand US dollars, whereas by 2022, this gap widened to 28,297 thousand US dollars. This indicates that the specific items being adjusted out of the current liability total have grown at a faster rate than the total liabilities themselves.
Proportional Impact of Adjustments
The ratio of adjusted current liabilities to total current liabilities remained relatively stable but showed a slight downward shift in the later years. In 2017, adjusted liabilities represented 83.9% of total current liabilities. By 2022, this proportion decreased to 79.5%, suggesting that the adjustments have become more significant relative to the overall short-term liability structure.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Adjustments to Total Liabilities

Abiomed Inc., adjusted total liabilities

US$ in thousands

Microsoft Excel
Mar 31, 2022 Mar 31, 2021 Mar 31, 2020 Mar 31, 2019 Mar 31, 2018 Mar 31, 2017
As Reported
Total liabilities 170,067 164,684 150,996 117,456 96,851 98,343
Adjustments
Add: Operating lease liability (before adoption of FASB Topic 842)1 — — — 14,274 10,089 7,462
Less: Deferred tax liabilities2 781 847 806 822 903 783
Less: Deferred revenue 26,362 24,322 19,147 16,393 14,970 10,495
Less: Product warranty 1,935 2,053 1,818 1,272 1,081 717
After Adjustment
Adjusted total liabilities 140,989 137,462 129,225 113,243 89,986 93,810

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).

1 Operating lease liability (before adoption of FASB Topic 842). See details »

2 Deferred tax liabilities. See details »


Total and adjusted total liabilities exhibit a consistent upward trajectory over the six-year period ending March 31, 2022. While a minor contraction occurred between 2017 and 2018, subsequent years show accelerated growth, particularly starting in 2019.

Total Liabilities Growth
Total liabilities increased from 98,343 thousand US dollars in 2017 to 170,067 thousand US dollars in 2022. The most significant period of expansion occurred between 2019 and 2020, during which total liabilities rose by approximately 33,540 thousand US dollars, representing a substantial increase in the company's overall obligations.
Adjusted Total Liabilities Trend
Adjusted total liabilities followed a parallel growth pattern, rising from 93,810 thousand US dollars in 2017 to 140,989 thousand US dollars in 2022. Although the trend mirrors that of total liabilities, the absolute values remained consistently lower, indicating a persistent set of adjustments applied to the total liability figure throughout the period.
Analysis of Liability Divergence
A notable widening of the gap between total and adjusted liabilities is observed beginning in 2020. In 2017, the variance between the two metrics was 4,533 thousand US dollars. By 2022, this variance expanded to 29,078 thousand US dollars. This indicates that the impact of the adjustments grew proportionally faster than the liabilities themselves, with the adjustment amount increasing more than sixfold over the observed period.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Adjustments to Stockholders’ Equity

Abiomed Inc., adjusted stockholders’ equity

US$ in thousands

Microsoft Excel
Mar 31, 2022 Mar 31, 2021 Mar 31, 2020 Mar 31, 2019 Mar 31, 2018 Mar 31, 2017
As Reported
Stockholders’ equity 1,503,326 1,329,675 1,065,466 936,890 689,524 452,071
Adjustments
Less: Net deferred tax assets (liabilities)1 9,771 10,533 42,530 76,680 69,843 33,940
Add: Allowance for credit losses 624 774 1,202 1,040 320 282
Add: Deferred revenue 26,362 24,322 19,147 16,393 14,970 10,495
Add: Product warranty 1,935 2,053 1,818 1,272 1,081 717
After Adjustment
Adjusted stockholders’ equity 1,522,476 1,346,291 1,045,103 878,915 636,052 429,625

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).

1 Net deferred tax assets (liabilities). See details »


A consistent upward trajectory is observed in both reported and adjusted stockholders' equity over the six-year period ending March 31, 2022. Total stockholders' equity grew from 452,071 thousand US dollars in 2017 to 1,503,326 thousand US dollars in 2022, indicating a significant expansion of the capital base.

Growth Trajectory
The reported stockholders' equity increased steadily each year, with the most pronounced growth occurring between 2017 and 2019. Adjusted stockholders' equity mirrored this growth pattern, rising from 429,625 thousand US dollars to 1,522,476 thousand US dollars over the same interval.
Equity Adjustment Analysis
A shift in the relationship between reported and adjusted equity is evident. From 2017 through 2020, adjusted stockholders' equity remained below the reported figures, with the widest gap occurring in 2019. Beginning in 2021, this trend reversed; adjusted stockholders' equity surpassed reported equity by 16,616 thousand US dollars, a trend that persisted into 2022 with a variance of 19,150 thousand US dollars.
Comparative Stability
Despite the change in the direction of the adjustments, the strong correlation between the reported and adjusted metrics suggests that the adjustments do not fundamentally alter the overarching trend of equity accumulation.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Adjustments to Capitalization Table

Abiomed Inc., adjusted capitalization table

US$ in thousands

Microsoft Excel
Mar 31, 2022 Mar 31, 2021 Mar 31, 2020 Mar 31, 2019 Mar 31, 2018 Mar 31, 2017
As Reported
Current portion of capital lease obligation — — — — — 799
Capital lease obligation, net of current portion — — — — — 15,539
Total reported debt — — — — — 16,338
Stockholders’ equity 1,503,326 1,329,675 1,065,466 936,890 689,524 452,071
Total reported capital 1,503,326 1,329,675 1,065,466 936,890 689,524 468,409
Adjustments to Debt
Add: Operating lease liability (before adoption of FASB Topic 842)1 — — — 14,274 10,089 7,462
Add: Operating lease liabilities in other current liabilities2 2,889 2,459 3,671 — — —
Add: Operating lease liabilities in other long-term liabilities3 6,618 3,657 8,549 — — —
Adjusted total debt 9,507 6,116 12,220 14,274 10,089 23,800
Adjustments to Equity
Less: Net deferred tax assets (liabilities)4 9,771 10,533 42,530 76,680 69,843 33,940
Add: Allowance for credit losses 624 774 1,202 1,040 320 282
Add: Deferred revenue 26,362 24,322 19,147 16,393 14,970 10,495
Add: Product warranty 1,935 2,053 1,818 1,272 1,081 717
Adjusted stockholders’ equity 1,522,476 1,346,291 1,045,103 878,915 636,052 429,625
After Adjustment
Adjusted total capital 1,531,983 1,352,407 1,057,323 893,189 646,141 453,425

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).

1 Operating lease liability (before adoption of FASB Topic 842). See details »

2 Operating lease liabilities in other current liabilities. See details »

3 Operating lease liabilities in other long-term liabilities. See details »

4 Net deferred tax assets (liabilities). See details »


The capitalization structure exhibits a consistent and substantial expansion between March 31, 2017, and March 31, 2022. This growth is primarily characterized by a significant increase in equity, while debt levels remained relatively low and fluctuated within a narrow range.

Equity Growth Trends
Stockholders' equity demonstrated a strong upward trajectory, increasing from 452.1 million in 2017 to 1.50 billion in 2022. Adjusted stockholders' equity followed a similar pattern, growing from 429.6 million to 1.52 billion over the same period. This indicates a sustained accumulation of capital and a strengthening of the entity's net worth.
Debt Profile and Leverage
Adjusted total debt remained minimal relative to the overall capital base. After a peak of 23.8 million in 2017, adjusted debt decreased to 10.1 million in 2018, fluctuated between 12.2 million and 14.3 million through 2020, and reached a low of 6.1 million in 2021 before ending at 9.5 million in 2022. This suggests a conservative approach to leverage.
Total Capitalization Analysis
Adjusted total capital rose from 453.4 million in 2017 to 1.53 billion in 2022. The alignment between total reported capital and adjusted total capital is high, as both metrics were driven almost exclusively by the expansion of equity. The difference between reported debt and adjusted debt suggests the accounting treatment of certain liabilities as debt-like obligations in the adjusted figures.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Adjustments to Revenues

Abiomed Inc., adjusted revenue

US$ in thousands

Microsoft Excel
12 months ended: Mar 31, 2022 Mar 31, 2021 Mar 31, 2020 Mar 31, 2019 Mar 31, 2018 Mar 31, 2017
As Reported
Revenue 1,031,753 847,522 840,883 769,432 593,749 445,304
Adjustment
Add: Increase (decrease) in deferred revenue 2,040 5,175 2,754 1,423 4,475 1,717
After Adjustment
Adjusted revenue 1,033,793 852,697 843,637 770,855 598,224 447,021

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).


A consistent upward trajectory in revenue is observed from the fiscal year ending March 31, 2017, through March 31, 2022. Total revenue grew from 445.3 million US dollars to 1.03 billion US dollars, reflecting a significant expansion of the top line over the six-year period.

Revenue Growth Patterns
Rapid growth was evident between 2017 and 2019, during which revenue increased from 445.3 million to 769.4 million US dollars. A period of relative stabilization occurred between 2020 and 2021, characterized by a minimal increase from 840.9 million to 847.5 million US dollars. Growth accelerated again in the final period, with revenue surpassing the 1 billion US dollar threshold by March 31, 2022.
Analysis of Revenue Adjustments
Adjusted revenue consistently remains higher than reported revenue across all observed periods. The variance between the two metrics is marginal, typically representing a small fraction of total turnover. The largest absolute adjustment occurred in 2021, with a difference of approximately 5.2 million US dollars, while the smallest adjustment occurred in 2019 at approximately 1.4 million US dollars.
Impact of Adjustments on Financial Trends
The adjustments applied to revenue do not materially alter the overall financial trend, as the adjusted figures mirror the growth and stabilization patterns of the reported revenue. The percentage difference remains low, indicating that the adjustments are non-material relative to the total scale of operations.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Adjustments to Reported Income

Abiomed Inc., adjusted net income

US$ in thousands

Microsoft Excel
12 months ended: Mar 31, 2022 Mar 31, 2021 Mar 31, 2020 Mar 31, 2019 Mar 31, 2018 Mar 31, 2017
As Reported
Net income 136,505 225,525 203,009 259,016 112,170 52,116
Adjustments
Add: Deferred income tax expense (benefit)1 2,413 29,380 32,953 (7,745) 42,624 25,803
Add: Increase (decrease) in allowance for credit losses (150) (428) 162 720 38 158
Add: Increase (decrease) in deferred revenue 2,040 5,175 2,754 1,423 4,475 1,717
Add: Increase (decrease) in product warranty (118) 235 546 191 364 (281)
Add: Other comprehensive income (loss) (15,715) (256) 3,500 (10,485) 16,402 (6,066)
After Adjustment
Adjusted net income 124,975 259,631 242,924 243,120 176,073 73,447

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).

1 Deferred income tax expense (benefit). See details »


The financial performance from 2017 to 2022 is characterized by a period of aggressive growth through 2021, followed by a significant contraction in the final fiscal year. Both reported and adjusted net income figures exhibit a similar trajectory, peaking between 2019 and 2021 before experiencing a sharp downturn in 2022.

Net Income Trajectory
Reported net income grew rapidly from 52,116 thousand in 2017 to a peak of 259,016 thousand in 2019. A period of volatility followed, with a decrease in 2020 to 203,009 thousand and a partial recovery in 2021 to 225,525 thousand. The 2022 fiscal year shows a substantial decline, with net income falling to 136,505 thousand.
Adjusted Net Income Trends
Adjusted net income demonstrated a consistent upward trend from 2017 through 2021, increasing from 73,447 thousand to its highest point of 259,631 thousand. Unlike the reported net income, the adjusted figure remained relatively stable between 2019 and 2021, suggesting that adjustments smoothed out the volatility seen in reported earnings during that window. However, a sharp decline is evident in 2022, falling to 124,975 thousand.
Analysis of Income Adjustments
The relationship between reported and adjusted net income fluctuates over the six-year period. In 2017, 2018, 2020, and 2021, adjusted net income was higher than reported net income, which indicates that non-cash charges or non-recurring expenses negatively impacted the reported results. Conversely, in 2019 and 2022, reported net income exceeded adjusted net income, suggesting the presence of one-time gains or favorable adjustments that were excluded from the adjusted performance metric.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?